Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
Aventyl Hydrochloride is an oral capsule small-molecule antidepressant approved by Eli Lilly in 1964. The specific mechanism of action and approved indications are not detailed in available data, but it represents a legacy psychiatric medication from the tricyclic era. This product is approaching loss of exclusivity and operates in a highly competitive therapeutic space.
This legacy product faces significant competitive pressure (30/100) with no current linked job openings, indicating a mature, low-priority brand with minimal team expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Aventyl offers limited career growth given zero linked job openings and approaching LOE. This assignment suits professionals managing legacy portfolio wind-down, supporting generic transition, or seeking stable, lower-intensity roles in psychiatric care.
Worked on AVENTYL HYDROCHLORIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.